Kidney stone removal technology developer Calyxo announced today that it closed a $32.7 million Series C financing round.
Pleasanton, California–based Calyxo develops the CVAC Aspiration system designed to use irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome.
According to a news release, Questa Capital and CRG led the Series C funding round completed today.
“We are excited to be moving into the next step of our evolution,” Calyxo President and CEO, Joe Catanese said in the release. “Kidney stone disease is a painful problem for patients, and it consumes vast amounts of healthcare resources each year. We believe our solutions will better meet the needs of kidney stone patients and transform the care of this condition. We look forward to applying this latest financing round toward further product development and the expansion of our team.”
Catanese previously co-founded NeoTract, which developed the UroLift system for treating lower urinary tract symptoms and was acquired by Teleflex for $1 billion in 2017. Catanese has now assembled a team and board for Calyxo that includes many of NeoTract’s founding team and key players, the company said.
“We are proud to invest in Calyxo and its groundbreaking kidney stone treatment technology,” Questa Capital founder and Managing Partner and Calyxo board member Ryan Drant said. “The company’s leadership team has a remarkable track record of recognizing significant unmet physician and patient needs within urology and bringing to market game-changing solutions to meet those needs. We look forward to supporting Calyxo through forthcoming development and commercialization milestones, and we are excited to see the team expand.”